Literature DB >> 26209383

Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma.

Dante Romagnoli1, Alessandra Marrazzo2, Stefano Ballestri3, Amedeo Lonardo2, Marco Bertolotti2.   

Abstract

We report on the first well-tolerated and successful use of sofosbuvir-based therapy in a patient in whom chronic infection with hepatitis C had preceded the development of B-cell non-Hodgkin's lymphoma. The patient had previously failed numerous attempts to clear the hepatitis C virus with traditional antiviral schedules. We demonstrate that sofosbuvir-based therapy resulted in cure of hepatitis C in a patient who had relapsed during combination therapy with an NS5A inhibitor, an NS3 protease inhibitor and ribavirin, as well as treatment failures to multiple courses of interferon-based therapy. This report also suggests that eradication of hepatitis C virus may result in the short-term prevention of B-cell non-Hodgkin's lymphoma relapse. The findings from our case require further validation in future cohorts of patients.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  B-cell non-Hodgkin’s lymphoma; Difficult-to-treat; Direct-acting antiviral agent; Hepatitis C virus; Sofosbuvir

Mesh:

Substances:

Year:  2015        PMID: 26209383     DOI: 10.1016/j.jcv.2015.05.023

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  2 in total

1.  Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma.

Authors:  Evan C Ewers; Phalgoon A Shah; Mark G Carmichael; Tomas M Ferguson
Journal:  Open Forum Infect Dis       Date:  2016-12-20       Impact factor: 3.835

Review 2.  Systemic manifestations of hepatitis C infection.

Authors:  Lydia Tang; Lauren Marcell; Shyam Kottilil
Journal:  Infect Agent Cancer       Date:  2016-05-23       Impact factor: 2.965

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.